Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms
Authors
Keywords
Algorithm, Renal cell cancer, Consensus, Diagnostic nodes
Journal
WORLD JOURNAL OF UROLOGY
Volume 35, Issue 4, Pages 641-648
Publisher
Springer Nature
Online
2016-08-03
DOI
10.1007/s00345-016-1903-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma
- (2016) R. Nadal et al. ANNALS OF ONCOLOGY
- European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma
- (2016) Robert J Motzer et al. LANCET ONCOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes
- (2015) T. Hundsberger et al. JOURNAL OF NEURO-ONCOLOGY
- NICE guidance on axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
- (2015) Nwamaka Umeweni et al. LANCET ONCOLOGY
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Renal-Cell Cancer — Targeting an Immune Checkpoint or Multiple Kinases
- (2015) David I. Quinn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes
- (2015) C. Rothermundt et al. ONCOLOGIST
- Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland
- (2015) Cédric M. Panje et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) B. Escudier et al. ANNALS OF ONCOLOGY
- Re: Pazopanib Versus Sunitinib in Metastatic Renal-cell Carcinoma
- (2014) Idir Ouzaid et al. EUROPEAN UROLOGY
- Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example
- (2014) Mauricio Burotto et al. PLoS One
- Objective consensus from decision trees
- (2014) Paul Martin Putora et al. Radiation Oncology
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2013) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Swarm-Based Medicine
- (2013) Paul Martin Putora et al. JOURNAL OF MEDICAL INTERNET RESEARCH
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now